KalVista Pharmaceuticals announced the UK Medicines and Healthcare products Regulatory Agency has awarded the Innovation Passport for sebetralstat, an investigational novel, oral plasma kallikrein inhibitor for the on-demand treatment of hereditary angioedema. The Innovation Passport is the first step in the UK’s Innovative Licensing and Access Pathway, which is designed to accelerate a product’s time to market and facilitate patient access to innovative medicines.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on KALV:
